Thermo Fisher Scientific announced that the Oncomine™ Comprehensive Assay Plus* is now available on the Ion Torrent™ Genexus™ System* helping accelerate precision oncology research. The Oncomine Comprehensive Assay Plus detects a broad range of genomic alterations in 517 genes and will now be able to deliver comprehensive genomic profiling (CGP) results as soon as the next day, enabled by Ion Torrent technology and easy, automated workflows..

赛默飞世尔科技宣布，Oncomine™ Comprehensive Assay Plus* 现已在 Ion Torrent™ Genexus™ 系统* 上可用，助力加速精准肿瘤学研究。Oncomine Comprehensive Assay Plus 可检测 517 个基因的广泛基因组变异，现在借助 Ion Torrent 技术和简单、自动化的操作流程，能够最快在次日提供全面的基因组分析 (CGP) 结果。

CGP facilitates the simultaneous analysis of a broad range of biomarkers in one test to maximize insights on the underlying oncogenic drivers in a timely manner. Already available on the Ion GeneStudio™ S5 systems*, the Oncomine Comprehensive Assay Plus detects single-nucleotide variants, insertions and deletions, copy number variations, and fusions.

CGP能够在一次检测中同时分析多种生物标志物，从而及时获得对潜在致癌驱动因素的深入洞察。已在Ion GeneStudio™ S5系统*上可用的Oncomine Comprehensive Assay Plus能够检测单核苷酸变异、插入和缺失、拷贝数变异以及融合。

Additionally, the assay detects genomic signatures such as homologous recombination deficiency (HRD), tumor mutational burden (TMB) and microsatellite instability (MSI). With the capabilities of the Genexus System, researchers can now detect a broad range of these important biomarkers, quickly and easily..

此外，该检测方法还能识别基因组特征，如同源重组缺陷（HRD）、肿瘤突变负荷（TMB）和微卫星不稳定性（MSI）。借助Genexus系统的能力，研究人员现在可以快速、轻松地检测到这些重要生物标志物的广泛范围。

“We have been waiting for this complete and rapid CGP solution that includes all the relevant biomarkers including TMB, MSI and HRD,” said Hector M Alcaraz, MS, Founder of Imagene Health, SA de CV, an early access user of the Oncomine Comprehensive Assay Plus on the Genexus System. “This will make CGP more accessible to our local markets so that we can drive the future of precision medicine forward.”.

“我们一直在等待这个包含所有相关生物标志物（包括TMB、MSI和HRD）的完整且快速的CGP解决方案，”Imagene Health, SA de CV的创始人Hector M Alcaraz说道，该机构是Genexus系统上Oncomine Comprehensive Assay Plus的早期使用用户。“这将使CGP在我们本地市场更易获取，从而推动精准医疗的未来发展。”

The Genexus System is an automated and integrated NGS platform capable of delivering NGS results as soon as the next day. With end-to-end automation that requires less hands-on time, the Genexus System makes genomic profiling accessible to more researchers with varying levels of experience. Now, with the Oncomine Comprehensive Assay Plus available on the Genexus System, research teams can leverage this end-to-end solution to deliver accurate and robust CGP results as soon as the next day..

Genexus系统是一个自动化且集成的NGS平台，能够在第二天就提供NGS结果。通过端到端的自动化流程，减少了手动操作时间，Genexus系统使更多不同经验水平的研究人员能够进行基因组分析。现在，随着Oncomine Comprehensive Assay Plus在Genexus系统上的可用性，研究团队可以利用这一端到端的解决方案，在第二天就获得准确且强大的CGP结果。

“In recent years, new genomic insights have played an essential role in advancing our understanding of human health and driving novel drug development,” said Kathy Davy, president of Clinical Next Generation Sequencing at Thermo Fisher Scientific. “The addition of the Oncomine Comprehensive Assay Plus on the Genexus System brings the benefits of rapid CGP to more labs, empowering researchers to leverage more comprehensive results at a much faster pace and accelerate what could be life-saving research.”.

“近年来，新的基因组学见解在增进我们对人类健康的理解以及推动新药开发方面发挥了至关重要的作用，”赛默飞世尔科技临床下一代测序部门总裁Kathy Davy说道。“在Genexus系统上添加Oncomine Comprehensive Assay Plus将快速CGP的优势带给更多实验室，使研究人员能够以更快速度利用更全面的结果，加速可能挽救生命的研究。”

For more information about the Oncomine Comprehensive Assay Plus on the Genexus System and how this is enabling research labs to accelerate oncology research, please visit thermofisher.com/oncomine-ocaplus.

有关Genexus系统上的Oncomine Comprehensive Assay Plus及其如何帮助研究实验室加速肿瘤学研究的更多信息，请访问thermofisher.com/oncomine-ocaplus。

*For Research Use Only. Not for use in diagnostic procedures.

*仅用于研究。不得用于诊断程序。

About Thermo Fisher Scientific

关于赛默飞世尔科技

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them.

赛默飞世尔科技公司是服务科学领域的全球领导者，年收入超过400亿美元。我们的使命是帮助客户使世界变得更健康、更清洁、更安全。无论我们的客户是在加速生命科学研究、解决复杂的分析难题、提高实验室生产力，还是通过诊断改善患者健康，或是开发和生产改变生命的疗法，我们都将全力支持他们。

Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com..

我们的全球团队通过行业领先的品牌（包括Thermo Scientific、Applied Biosystems、Invitrogen、Fisher Scientific、Unity Lab Services、Patheon和PPD）提供无与伦比的创新技术、采购便利性和医药服务组合。欲了解更多信息，请访问www.thermofisher.com。